Amylyx acquires avexitide GLP-1ra post-bariatric hypoglycaemia from Eiger BioPharmaceuticals
Amylyx Pharmaceuticals has acquired avexitide from Eiger BioPharmaceuticals, an investigational, first-in-class glucagon-like peptide-1...
top of page
Browse by category
Search
Eiger BioPharmaceuticals to focus Avexitide for hyperinsulinemic hypoglycaemia indications
Eiger BioPharmaceuticals has revealed it will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycaemia...
Use of avexitide in patients with post-bariatric hypoglycaemia and hyperinsulinemic hypoglycaemia
Phase 2b results of avexitide (Eiger BioPharmaceuticals) in patients with post-bariatric hypoglycemia (PBH) and hyperinsulinemic...
PREVENT Study: Positive results of Avexitide in post-bariatric hypoglycaemia patients
Eiger BioPharmaceuticals has announced positive results from the Phase 2 PREVENT study of Avexitide in patients with severe...
Browse by tag
bottom of page